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Introduction: The last decade was marked by the widespread use of molecular biological 
agents in combination with 5-FU / oxaliplatin or irinotecan-containing regimens in the 
treatment of cancer. Such biological medicines have significantly increased the costs of 
oncological treatment, leading to concerns about the future sustainability of drug policy 
and, as a consequence, health systems with universal access to health care. In the case 
of Brazil, the tree MoAbs BEVACIZUMAB(BEVA), CETUXIMAB(CETUX), 
PANITUMUMAB(PANIT) and one tirosine kinase inhibitor REGORAFENIB(REGORA) 
compared in this study can only be used by the patient when there is a litigation against 
the State, since they are not incorporated into the Single System of Health-SUS. 
Objectives: To evaluate the  evolution  number of litigation cases and expenditure with 
monoclonal antibodies(MoAbs) (Bevacizumab, Cetuximab and Panitumumab) and 
tirosine kinase inhibitor (Regorafenib)  for the treatment of cancer in Minas Gerais-Brazil. 
Method: Retrospective descriptive study whose judicial information was extracted from 
the database of the Minas Gerais State Secretariat - SES-MG. The judicial actions were 
filed against the State of Minas Gerais for Cancer treatment and refer to the period from 
January 2009 to December 2016. The study was cut from the judicialized MoAbs (BEVA, 
CETUX, PANIT) and tirosin kinase inhibitor (REGORA) for the treatment of Colorectal 
Cancer (CCR). The cost of the treatments was calculated based on the prices of the 
Câmara de Regulação do Mercado de Medicamentos (CMED) ANVISA, taking into 
account the official dollar exchange rate of the Central Bank on January 31, 2018 and 
there is no adjustment for inflation. Results and discussion: Preliminary results showed 
that in the period between 2009 and 2016, 1024 lawsuits were filed against the State of 
Minas Gerais for cancer treatment, making 766 for BEVA, 206 for CETUX, 35 for PANIT 
and 17 for REGORA . The total cost obtained considering a 6-month overall survival for 
each patient was $ 22,260,536. In Brazil, the growing number of litigation and drug costs 
(BEVA, CETUX, PANIT and REGORA) per year is worrying, considering the increase of 
5.100% for judicial actions and 1899% for treatment costs in the period 2009 to 2016 
(TABLE 1). Conclusion:  The exponential increase in lawsuits against the State of Minas 
Gerais demonstrates the growing pressure on the resources available to attend a 
reduced number of patients, who are available to judicialize treatments outside universal 
health coverage, which is already guaranteed right by the Brazilian constitution. 
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Table 1.  Evolution number of litigation cases and expenditure on BEVA, CETUX, PANIT 
and REGORA/ Year in Minas Gerais ± Brazil, 2009-2016 
 
Evolution number of  litigation cases and expenditure on Beva, Cetux,Panit and Regora/ Year in Minas Gerais ± Brazil, 2009-2016 
  2009 2010 2011 2012 2013 2014 2015 2016 Total 
% increase 
2009 -2016 
Bevacizumab 4 10 35 89 147 171 159 151 766 3775 
Cetuximab 0 4 13 36 44 36 41 32 206 800 
Panitumumab 0 0 0 2 3 6 8 16 35 800 
Regorafenib 0 0 0 1 1 6 4 5 17 500 
Total cases 4 14 48 128 195 219 212 204 1024 5100 
total cost $ 
(dolar)  
 
$220.4
71,00  
 
$331.915,0
0  
 $ 
1.122.915,0
0  
 $ 
3.007.052,00  
 $ 
4.350.203,00  
 $ 
4.507.21
8,00  
 $ 
4.533.32
4,00  
 $ 
4.187.4
38,00  
 $   
22.260.536,0
0  
1899 
 
 
 
